Cullinan Oncology, Inc. (CGEM) Misses Q2 EPS by 25c

Cullinan Oncology, Inc. (NASDAQ: CGEM) reported Q2 EPS of ($1.07), $0.25 worse than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Cullinan Oncology, Inc. (CGEM) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• BNP Paribas Exane Upgrades Novonesis A/S (NSISB:DC) to Neutral
• JPMorgan Starts Kanzhun Ltd (2076:HK) at Overweight